RKLB vs. AVAV: Which Stock Looks Better in the Space Race?

Rocket Lab (RKLB) is benefiting from sustained launch cadence and government wins — completing its 21st Electron launch of 2025 for iQPS, deploying seven satellites for that customer with five more launches planned, and securing a U.S. Space Development Agency contract to build 18 Tracking Layer Tranche 3 satellites; Zacks pegs RKLB’s 2025 loss at $0.20 and revenue at $600.5M (+37.7% y/y). AeroVironment (AVAV) won a potential $874.3M five‑year Army contract and delivered two JLTV‑mounted counter‑UAS laser systems, with Zacks forecasting fiscal‑2026 EPS of $3.48 and revenue of $2.0B (implying ~143.7% growth), though its EPS estimates have recently been revised down. Valuation and performance contrast sharply: RKLB has outperformed over the past year (+191.5% vs AVAV +59.5%) but trades at a rich forward P/S (~48.8x) versus AVAV (~5.8x); both stocks carry a Zacks Rank #3 (Hold).

Analysis

Market structure: Small-launch providers (RKLB), satellite manufacturers and COTS space-systems suppliers are the principal beneficiaries as government & commercial procurement rises — incumbents with higher cost structures face pricing pressure and potential share loss over 1–3 years. RKLB's government awards (SDA, Space Force) increase durable revenue visibility but its forward P/S ~49x implies market expectations of continued rapid topline expansion; AVAV trades at ~5.8x P/S and benefits from large defense backlog that de-risks near-term cash flow.

Risk assessment: Tail risks include a single major launch failure (RKLB) or a cancelled/missed Army foreign-military-sale tranche (AVAV) — either can trigger >30% moves within days. Near-term (0–3 months) watch for contract-delivery slippage and FY26 estimate revisions; medium-term (3–12 months) watch cadence of Electron launches and AVAV program execution; long-term (2–5 years) funding shifts in US defense budgets and export controls could materially re-rate both.

Trade implications: Use relative-value structures: pair long AVAV / short RKLB to capture P/S mean reversion while hedging macro equity risk; if taking directional bets, prefer AVAV on a 6–12 month horizon sized 2–4% portfolio for value capture and buy protective 3–6 month put spreads on RKLB instead of naked shorts. Options strategies: buy RKLB 3–6 month 15–25% OTM put spreads to hedge upside exposure, and sell AVAV 3-month covered calls against newly initiated positions to enhance yield.

Contrarian angles: Consensus leans toward RKLB growth superiority but underestimates valuation sensitivity — a single revenue miss could wipe out implied growth premium. AVAV’s estimate downgrades are probably timing-related (lumpy FMS bookings) so downside from current levels may be limited; historical parallel: post-contract small defense names often outperform after 6–9 months once backlog converts. Unintended consequence: aggressive government awards can invite new entrants, depressing margins across small-launch and space hardware sectors.

Key Decisions for Investors

• Establish a 2–4% long position in AVAV (size to portfolio risk) with a 6–12 month horizon; add another 1–2% if shares drop >10% or after a confirmed positive quarterly backlog conversion; set stop-loss at -18% to limit downside.
• Initiate a dollar-neutral pair: long AVAV 1.5% / short RKLB 1.5% to exploit P/S gap (48.8x vs 5.8x) over a 3–12 month window; rebalance monthly and tighten short if RKLB posts two consecutive positive earnings surprises.
• Buy RKLB 3–6 month put spread (buy 1 15–25% OTM put, sell lower strike) sized to offset 50–75% of any existing RKLB long exposure, limiting cost while protecting against >20% downside from a launch failure or missed revenue.
• Sell 3-month covered calls on newly purchased AVAV positions at ~10% OTM to collect premium; concurrently, sell cash-secured AVAV puts 6 months 10% below market to scale into additional exposure if contract timing causes short-term weakness.
• Monitor U.S. defense budget and SDA announcements over the next 30–60 days: if proposed cuts to space programs exceed 5% or a major program is delayed, reduce RKLB gross exposure by 50% and re-allocate to AVAV or cash.